Intractable seizures are just one manifestation of 'refractory epilepsy', which can be recognized as a distinct condition with multifaceted dimensions, including neurobiochemical plastic changes, cognitive decline and psychosocial dysfunction, leading to dependent behaviour and a restricted lifestyle. The biological basis of 'refractoriness' is likely to be multifactorial, and may include the severity of the syndrome and/or underlying neuropathology, abnormal reorganization of neuronal circuitry, alteration in neurotransmitter receptors, ion channelopathies, reactive autoimmunity, and impaired antiepileptic drug (AED) penetration to the seizure focus. Some of these deleterious changes may be a consequence of recurrent seizures. We hypothesize that 'refractory epilepsy' may be prevented by interrupting this self-perpetuating progression. There is increasing evidence that these patients can be identified early in the clinical course and, thus, be targeted early for effective therapeutic intervention. Failure of two first-line AEDs due to lack of efficacy or poor tolerability should prompt consideration of epilepsy surgery in a patient with a resectable brain abnormality. For the majority not suitable for 'curative' surgery, AEDs should be combined with the aim of achieving 'synergism'. This strategy has the potential to improve outcome by preventing the insidious progression to intractable 'refractoriness' and a downward spiralling quality of life.
INTRODUCTION
Epilepsy affects 4-10 per 1000 people 1 , which translates into approximately 50 million sufferers worldwide 2 . The prevalence is set to rise with the ageing of the population 3 . Despite antiepileptic drug (AED) treatment, up to one-third of patients continue to have seizures 4, 5 . Many will have 'refractory epilepsy'. We wish to propose a hypothesis for the conceptual understanding and prevention of refractory epilepsy based on accumulated laboratory findings, and an improved knowledge of the 'natural history' of treated epilepsy 5 .
REFRACTORY EPILEPSY AS A DISTINCT CONDITION
Although criteria for defining 'refractory epilepsy' are elusive e.g. number of drugs tried, dose of drugs, duration of treatment etc. 6, 7 , a hard core of 20-30% of patients continue to have seizures that appear to be resistant to all pharmacological manipulations 8 . These patients are usually treated with multiple AEDs, which, in combination, may produce sedative and behavioural toxicity 9, 10 . High seizure frequency, prolonged seizures and episodes of status epilepticus can lead to cognitive decline 11 . A long period of imperfect seizure control produces disturbed psychosocial functioning resulting, for instance, in poor academic achievement, diminished self-esteem, low rates of marriage, dependent behaviour, and restricted lifestyle, all leading to unsatisfactory quality of life 12, 13 . In addition, refractory epilepsy is associated with excess mortality, particularly due to sudden unexpected death 14 . 'Refractory epilepsy', therefore, may be better understood as a distinct condition comprising of a constellation of disabilities with recurrent seizures being just one of its manifestations (Table 1) . 
REFRACTORY EPILEPSY AS A MULTIFACTORIAL CONDITION
With the identification of the genetic defects in several idiopathic epilepsy syndromes, important insights into the mechanisms underlying the pathogenesis of epilepsy are emerging 15 . However, what causes epilepsy to become 'refractory' has not been well studied. The biological basis of 'refractoriness' is likely to be multifactorial and variable. Some possible contributing factors are listed in Table 2 . Reactive autoimmunity e.g. autoantibodies against glutamic acid decarboxylase Impaired antiepileptic drug penetration e.g. P-glycoprotein expression at blood-brain barrier GABA = γ -aminobutyric acid.
Syndromic classification
Among the idiopathic (genetic) epilepsies, prognosis is often determined by the behaviour of the underlying syndrome 16 . Some (e.g. Rolandic epilepsy) appear to be 'benign' and may be outgrown by the child. Others (e.g. juvenile myoclonic epilepsy) respond well to AEDs, but are prone to relapse when drugs are withdrawn 17 . A few, such as the devastating encephalopathic disorders of infancy, have no consistently effective treatment 18 .
Gross pathology
Similar heterogeneity in outcome is beginning to be recognized in the symptomatic epilepsies. Outcome studies have provided evidence that certain structural abnormalities, particularly hippocampal sclerosis (HS) and cortical dysplasia (CD), are more likely to produce pharmacoresistant epilepsy than other pathologies 19 . This again suggests that response to AED treatment is influenced by the causative neuropathology 20 . In our prospective study of 550 patients with localization-related epilepsy, HS and CD were also associated with the worst prognosis 21 . However, marked variability in response to treatment was observed within any given aetiological group, so that some patients remained seizurefree after withdrawal from AED therapy whereas others continued to have seizures despite taking polypharmacy with up to four AEDs. This implies that outcome is affected by factors other than the gross pathology.
Neuronal circuitry and neurotransmitter receptors
These factors may include abnormalities in neuronal circuitry and neurotransmitter receptors. Such changes have been most extensively studied in HS, where there is selective neuronal loss in the CA1 and CA4 regions of the hippocampus with gliosis and 'sprouting' of mossy fibres, which may lead to a hyperexcitable state 22, 23 . Reorganization of mossy fibre synapses can also be observed in cases other than HS, such as in some models of generalized motor and absence seizures 24 . Changes in γ -aminobutyric acid (GABA, inhibitory) and glutamate (excitatory) neurotransmitter receptors, in terms of their composition, sensitivity and distribution, have been reported in the epileptic hippocampus 25, 26 . However, the direction of the changes is not consistent and how they may alter drug response has not been clearly defined 27 .
Ion channelopathies
An increasing number of channelopathies, including mutations in ligand-gated and voltage-gated ion channels, are being identified in human genetic epilepsies [28] [29] [30] [31] [32] . It has been shown in vitro that the mutated nicotinic receptors responsible for some cases of autosomal dominant nocturnal frontal epilepsy are more responsive to carbamazepine than their wild-type counterparts 33 . Mutations in ion channels, therefore, may play a role in the genesis of refractory epilepsy by altering response to AEDs.
Autoimmunity
There has been renewed interest in the potential role of autoimmunity in the manifestation and control of epilepsy 34 . Circulating antibodies to the GluR3 subunit of the glutamate receptor have been found in some patients with Rasmussen's encephalitis, a condition associated with intractable seizures often requiring radical surgery 35 . AntiGM1 antibodies, a proconvulsant in animal models, have been reported in a few patients with refractory partialonset seizures 36 . More recently, autoantibodies to glutamic acid decarboxylase, which catalyses the conversion of glutamate to GABA, have been detected in patients with drug-resistant epilepsy [37] [38] [39] . Although these autoantibodies all have 'theoretical' relevance to the epileptogenic process, their relationship to 'refractoriness' is unclear.
AED penetration across the blood-brain barrier
Over-expression of the drug transporter Pglycoprotein (P-gp), encoded by the multidrug resistance (MDR) gene, has been detected in brain tissues resected from patients undergoing epilepsy surgery 40 . P-gp 'pumps' drugs out of cells back into the blood stream and is expressed in many blood-tissue barriers. It is situated on the capillary endothelial cells where it contributes to the integrity of the blood-brain barrier 41 . Over-expression of Pgp by malignant cells is believed to account for their resistance to anticancer agents 42 . Similarly, localized over-expression of P-gp (or other similar families of transporter) around the seizure focus might inhibit the penetration of AEDs to the intended site of action, leading to 'multidrug resistant' epilepsy. Recent work suggests that some AEDs are substrates for P-gp 43 . More studies are required to confirm this.
REFRACTORY EPILEPSY AS A PROGRESSIVE CONDITION Experimental evidence
There is a substantial body of experimental evidence to support the concept that refractory epilepsy may be self-perpetuating. The most thoroughly studied substrate is that arising from the mesial temporal lobe 44 . Recurrent seizures, particularly those involving the limbic structures, are recognized to cause enduring disturbances in neuronal function independent of underlying pathology 24, 26, 45 . Characteristic patterns of neuronal loss and mossy fibre sprouting associated with human temporal lobe epilepsy can be produced by prolonged experimental seizures [46] [47] [48] [49] . Synaptic reorganization in the mossy fibre axons of hippocampal dentate granule cells into the inner molecular layer of the dentate gyrus 50 can form functional recurrent excitatory synapses which, in the presence of reduced inhibition, could promote seizures 51 . Whether a brief seizure or even a cluster of events is sufficient to destroy neurons is less certain, but the degree of neuronal loss in susceptible regions of the hippocampus has been shown to correlate with the number of kindled-seizures 52 . Even a single kindled seizure can induce apoptotic neuronal death in the dentate gyrus 53 .
Long-lasting changes in excitatory and inhibitory neurotransmitter receptors and ion channels have been documented in these animal models of human epilepsy 27, 54 . Seizures are also recognized to trigger a cascade of gene expression including the immediate early genes such as c-fos 55 , followed by neurotrophic factors 51 , and a variety of late genes encoding a range of peptides, receptors and cytoskeletal proteins 56 .
The functional consequences of such neuronal plasticity remain to be fully elucidated, but these alterations may lead to a deleterious combination of disinhibition and hyperexcitability 48, 57 . Some of these changes may also account for the phenomenon of secondary epileptogenesis, which is well-described in animal models of focal epilepsy. In this scenario, a primary epileptogenic lesion is able to induce epileptiform behaviour in an initially normal cell population via recurrent discharges to create a 'mirror focus' which, in time, becomes an independent source of epileptic activity 58 .
Clinical evidence
Are there data to support such self-perpetuation in human epilepsy? Recent advances in neuroimaging have allowed in vivo documentation of hippocampal neuronal loss following prolonged febrile seizures 59 and progressive hippocampal atrophy in chronic refractory temporal lobe epilepsy by serial magnetic resonance imaging 60 . Other recent neuroimaging studies have reported a correlation of increasing duration of epilepsy and/or numbers of seizures with more severe neuronal loss and dysfunction in temporal lobe epilepsy [61] [62] [63] . A long history of seizures prior to epilepsy surgery is associated with a higher risk of relapse, supporting the notion of secondary epileptogenesis in unresected tissue as a result of recurrent seizures 64 . Other surgical studies have reported more severe cognitive impairment in patients with longer duration of temporal lobe epilepsy 65 . Significantly, such associations have persisted even in patients who became seizure-free after temporal lobectomy.
Whether such progression can be observed in other epilepsy syndromes has been less well studied. Population-based epidemiological studies have traditionally failed to demonstrate the self-perpetuating effect of repeated seizures, particularly in children 16, 66 . Randomized trials suggest that while AEDs may prevent the immediate occurrence of seizures associated with febrile illness in children 67 or head injury 68 , the long-term risk of epilepsy is unaffected. However, these 'acute symptomatic' seizures are clearly provoked and would not fulfil the diagnostic criteria for epilepsy. Electroclinical studies in patients with tumour-associated epilepsy support the operation of secondary epileptogenesis 58, 69 . In our recent long-term outcome study of 470 adolescents and adults with newly diagnosed epilepsy, 47% became seizure-free on the first AED, 13% on a second monotherapy, but only 1% on the third drug 5 . The probability of attaining seizurefreedom declined rapidly and progressively with successive AED regimens after the first two treatment manipulations 70 .
Lastly, outcome studies often focus purely on seizure control without consideration of the cognitive and psychosocial aspects of epilepsy. There is evidence to suggest that neuropsychological dysfunction may not be reversible when the seizure disorder comes under control 64 . Surgical outcome studies indicate that even when the procedure is successful in eliminating seizures, patients with a long history of epilepsy often do not gain employment, marry, or have children, but rather remain dependent on family and the welfare system 71 . Such irreversibility may also explain why patients with childhood-onset epilepsy suffer social and educational disadvantages in adulthood well after entering remission 13 .
REFRACTORY EPILEPSY AS A PREVENTABLE CONDITION
Can these deleterious neuronal and psychosocial changes that characterize refractory epilepsy be prevented by therapeutic intervention? Although epileptogenesis is a potential target 72, 73 and some AEDs have demonstrated ability to retard the epileptogenic process in animal models 74 , the underlying neuropathology and the syndromic classification are at present considered to be constitutively determined. However, other changes described above may have developed with time as a result of uncontrolled seizures. It is tempting to hypothesize that by interrupting this self-perpetuating process early, the progression of seizure-related neurobiological, cognitive and psychosocial dysfunction might be halted or even reversed.
Early identification of refractory epilepsy
This hypothesis contains two important assumptions. First, it is possible to identify patients at risk of developing refractory epilepsy early in the disease process so that effective therapeutic interventions can be applied. Observational studies have traditionally highlighted the poor prognostic value of factors such as an underlying structural abnormality, high number/frequency of seizures, and abnormal electroencephalographic findings 6 . Recently, we have demonstrated that response to the first AED is a powerful prognostic indicator. This factor was particularly predictive among patients in whom treatment with the first drug was ineffective; only 11% of such patients subsequently became seizurefree, compared with 41% of the patients who had intolerable side effects and 55% of those with an idiosyncratic reaction to the first drug 5 . Therefore, in many patients, refractory epilepsy declares itself early.
Effective therapeutic interventions
Secondly and equally important, effective therapeutic interventions must exist for this group of patients. The management of epilepsy is undergoing a revolution. Advances in neuroimaging have improved the identification of suitable candidates for epilepsy surgery, which can render up to 90% of selected patient groups seizure-free. The most well-defined are those with HS 75 . The timing of surgery remains controversial. Since secondary epileptogenesis at distant sites may develop with uncontrolled seizures 64 , early surgery to avoid deterioration in seizure control and controllability has been advocated. To test this notion, a randomized controlled trial has been designed to compare early and delayed surgery in patients with mesial temporal lobe epilepsy who have failed two AEDs 71 .
Parallel to the advances in surgery, nine new AEDs have been licensed over the past decade. This expansion of the pharmacological armamentarium has rekindled interest in searching for 'synergistic' AED combinations 76 . The argument against combination therapy traditionally has been its propensity to produce greater toxicity without substantial improvement in outcome 77 . However, some of the newer agents may be better tolerated than their older counterparts 78 , potentially enhancing their overall effectiveness 79 . Their mechanistic diversity holds out the possibility of 'rational' polytherapy. Although data directly evaluating the effectiveness of AED combinations are scarce, 'synergistic' effects of certain combinations have been explored in laboratory and clinical studies, particularly those involving the concomitant use of a sodium channel blocking AED with one that enhances GABA-ergic inhibition or has multiple mechanisms of action 80 . A notable example is the combination of valproic acid and lamotrigine 75, 81 . Combining drugs with different mechanisms of action to improve efficacy is common practice in the treatment of other neurological (e.g. Parkinson's disease) and non-neurological conditions (e.g. heart failure). Well-designed studies are required to examine more fully whether this approach can be adopted universally in the management of epilepsy.
A WORKING HYPOTHESIS
Based on these considerations, we wish to propose a strategic plan for managing epilepsy from the outset. Such a rational approach is particularly important for 'high risk' patients, including those with a known or probable structural cerebral abnormality (especially certain pathologies such as HS and CD), or other poor prognostic clinical factors.
The aim of treatment in all patients should be the maintenance of a normal lifestyle by complete seizure control with no side-effects, given that the majority will respond to monotherapy and require lifelong treatment. When choosing the first AED, an accurate classification of the seizure(s) and epilepsy syndrome is of paramount importance 82 . In many situations, more than one AED may be efficacious. Since significant differences in efficacy between the AEDs licensed for monotherapy use have not been demonstrated for the common seizure types in randomized clinical trials [83] [84] [85] [86] [87] [88] [89] [90] [91] [92] [93] [94] , the choice of medication should take into consideration other factors such as the individual characteristics of the patients (age, gender and pregnancy plan, body habitus, concomitant disease and medications, etc) and the drugs (range of efficacy, tolerability, side effect and interaction profile). In this regard, efficacy and tolerability should both be considered when assessing the effectiveness of an AED.
If the first AED is not tolerated or the patient develops an idiosyncratic reaction, obviously the drug should be substituted. But if seizure control remains suboptimal despite the patient being able to tolerate a substantial dose of the first AED, as explored previously, it is less clear whether the drug should be substituted or another drug should be added to seek a 'synergistic' effect 70 . A randomized trial comparing substitution and combination therapy after failure of the first AED is underway in Glasgow. At present, the decision to substitute or combine should, among other factors, depends on the extent of the response to the first AED and the presence or absence of side-effects.
Our outcome data 5 support the assertion that failure of two first-line AEDs as monotherapy due to lack of efficacy should prompt consideration of epilepsy surgery in a patient with a resectable brain abnormality, in particular HS 71 . For the majority of patients not suitable for 'curative' surgery, two (or at most three) AEDs should be combined in a 'rational' fashion 95 . This should involve consideration of mechanism of action, as well as the range of efficacy, propensity for adverse interactions (pharmacokinetic and pharmacodynamic), and side-effect profile.
Conceptualization of refractory epilepsy as a distinct condition characterized by progressive neuronal, cognitive and psychosocial deterioration would allow a better appreciation of its multifaceted dimensions. We propose that failure of two first line AEDs due to lack of efficacy or poor tolerability should prompt consideration of epilepsy surgery or combination AED therapy with the aim of achieving 'synergy'. This strategy has the potential to improve outcome by preventing the insidious progression to intractable 'refractoriness' and a downward spiralling quality of life.
